Korea Exchange · Healthcare
Dong-A ST stock from India: price, numbers and tax
Dong-A ST (170900) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Dong-A ST at a glance
- Price
- ₩34,950.00-₩450.00 (1.27%)
- Market cap
- ₩337.05B
- Day range
- ₩34,750.00 – ₩35,650.00
- P/E
- -57.16
- Dividend yield
- 2.00%
- Volume
- 3.76K
- 1 month
- -2.51%
- 6 months
- -22.93%
- YTD
- -33.43%
- 1 year
- -9.89%
- 5 years
- -41.74%
Dong-A ST statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩808.8B | ₩697.9B | ₩664.0B | ₩635.4B | ₩593.2B |
| Gross profit | ₩356.5B | ₩340.2B | ₩322.2B | ₩315.4B | ₩293.9B |
| Operating income | ₩618.3M | −₩25.0B | ₩11.2B | ₩16.7B | ₩21.4B |
| Net income | −₩28.6B | −₩1.2B | ₩11.1B | ₩13.6B | ₩12.8B |
| Earnings per share | −₩2,970.54 | −₩141.41 | ₩1,474.18 | ₩1,543.95 | ₩1,459.74 |
| EBITDA | ₩33.4B | ₩29.0B | ₩45.1B | ₩49.4B | ₩35.5B |
| Total assets | ₩1.4T | ₩1.4T | ₩1.3T | ₩1.2T | ₩1.1T |
| Total debt | ₩537.1B | ₩495.7B | ₩406.7B | ₩312.2B | ₩300.6B |
| Cash and short-term investments | ₩291.7B | ₩301.1B | ₩286.4B | ₩289.3B | ₩304.5B |
| Shareholders' equity | ₩642.7B | ₩670.3B | ₩657.4B | ₩671.6B | ₩656.4B |
| Operating cash flow | ₩12.0B | −₩11.8B | ₩3.4B | ₩32.9B | ₩49.4B |
| Free cash flow | −₩10.1B | −₩43.9B | −₩38.7B | −₩36.0B | −₩31.1B |
| Capital expenditure | −₩22.1B | −₩32.1B | −₩42.0B | −₩68.9B | −₩80.4B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| JW Pharmaceutical | 001060.KS | ₩26,350.00 | ₩608.52B |
| JW Pharmaceutical | 001067.KS | ₩49,950.00 | ₩461.95B |
| HLB Pharmaceutical | 047920.KQ | ₩13,130.00 | ₩430.65B |
| Bukwang Pharmaceutical | 003000.KS | ₩4,055.00 | ₩400.09B |
| JW Pharmaceutical | 001065.KS | ₩21,900.00 | ₩377.50B |
| EuBiologics | 206650.KQ | ₩8,420.00 | ₩309.21B |
| Huons | 243070.KQ | ₩19,000.00 | ₩221.38B |
| BNC Korea | 256840.KQ | ₩3,060.00 | ₩209.29B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Dong-A ST from India
What Dong-A ST does
Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Dong-A ST operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Dong-A ST shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.